Talis Biomedical Corp is a molecular diagnostics company that develops point-of-care testing solutions for infectious diseases. The company’s technology leverages sample-to-answer automation to deliver rapid, lab-quality results outside of traditional laboratory settings. Talis Biomedical focuses on simplifying complex molecular assays to enable broader access in clinical laboratories, urgent care facilities and other decentralized testing environments.
The company’s flagship Talis One platform integrates proprietary reagents, single-use test cartridges and a compact analyzer to automate the workflow from extracted sample to result. Talis One has received U.S. FDA Emergency Use Authorization and a CLIA waiver for its SARS-CoV-2 molecular assay, allowing healthcare providers to perform high-sensitivity COVID-19 testing with minimal training. The platform can deliver results in under an hour.
Beyond its COVID-19 test, Talis Biomedical is advancing additional assays on the Talis One system, including multiplex panels for respiratory pathogens such as influenza and RSV. The company’s pipeline also explores infectious disease applications in underserved and point-of-care markets, aiming to address broader public health needs. Talis Biomedical collaborates with distributors and channel partners to expand its commercial reach globally.
Headquartered in Richmond, Victoria, Australia, Talis Biomedical is publicly traded on the NASDAQ under the ticker TLIS. The company serves healthcare customers across North America, Europe and the Asia-Pacific region, focusing on scalable diagnostic solutions that bring molecular testing capabilities closer to patients and clinicians.
AI Generated. May Contain Errors.
